Cover Image

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

Background: The clinical selection of three CDK4/6 inhibitors presents a challenging issue, owing to the absence of distinct clinical case characteristics, biomarkers, and their comparable clinical benefits in progression-free survival and overall survival To inform clinical treatment decisions, we...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dongqing Pu (Author), Yue Wu (Author), Debo Xu (Author), Guangxi Shi (Author), Hanhan Chen (Author), Dandan Feng (Author), Mengdi Zhang (Author), Jingwei Li (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
by: Corona SP, et al.
Published: (2018)

The clinical and pathological characteristics of lipid-rich carcinoma of the breast: an analysis of 98 published patients
by: Mengdi Zhang, et al.
Published: (2023)

Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis
by: Zhihao Zhang, et al.
Published: (2024)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
by: Mariane Teodoro Fernandes, et al.
Published: (2018)

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2- breast cancer treated with CDK4/6 inhibitors and endocrine therapy
by: Barbara Tagliaferri, et al.
Published: (2023)

Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution
by: Maria Inês Teodoro, et al.
Published: (2024)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Vera Martins, et al.
Published: (2023)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Jinhua Chen, et al.
Published: (2024)

Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis
by: Xin Guan, et al.
Published: (2024)

Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer
by: Edoardo Mortato, et al.
Published: (2024)

Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review
by: Federica Martorana, et al.
Published: (2024)

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
by: Lu-Qi Cao, et al.
Published: (2024)

HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
by: Rosalba Torrisi, et al.
Published: (2023)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
by: Ratnakar Reddy Kuchukulla, et al.
Published: (2022)

Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews
by: Letian Yang, et al.
Published: (2022)

Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018)

Association Between Folate and Health Outcomes: An Umbrella Review of Meta-Analyses
by: Yacong Bo, et al.
Published: (2020)

Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
by: Jiamin Qiu, et al.
Published: (2024)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow's oncologists
by: L. G. Zhukova, et al.
Published: (2020)

Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database
by: Yoshihiro Noguchi, et al.
Published: (2018)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
by: Chen Hu, et al.
Published: (2023)

CDK inhibitors for muscle stem cell differentiation and self-renewal
by: Amrudha Mohan, et al.
Published: (2017)

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings
by: Nina Galipeau, et al.
Published: (2019)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023)

Virtual Reality in Clinical Nursing Practice Over the Past 10 Years: Umbrella Review of Meta-Analyses
by: Yanjie Hu, et al.
Published: (2023)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
by: Abdel-Razeq H, et al.
Published: (2022)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
by: Zhen Li, et al.
Published: (2020)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
by: Amrallah A. Mohammed, et al.
Published: (2019)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
by: Chao-Yue Sun, et al.
Published: (2022)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
by: Milena M Murray, et al.
Published: (2023)

Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
by: Xiaolong Yue, et al.
Published: (2024)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
by: Hanzhi Liang, et al.
Published: (2022)

Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses
by: Kiarash Tanha, et al.
Published: (2021)

The association between air pollution and obesity: an umbrella review of meta-analyses and systematic reviews
by: Chengwen Luo, et al.
Published: (2024)